Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Armata Pharmaceuticals Inc ARMP

Healthcare Biotechnology
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:ARMP)

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

PR Newswire November 18, 2025

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

PR Newswire November 12, 2025

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

PR Newswire November 10, 2025

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025(TM)

PR Newswire October 22, 2025

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025(TM)

PR Newswire October 14, 2025

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

PR Newswire September 8, 2025

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

PR Newswire September 4, 2025

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

PR Newswire August 12, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

PR Newswire May 19, 2025
View More News ››

Opinion & Analysis (NYSEAM:ARMP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:ARMP)

Armata Pharmaceuticals, Inc. (ARMP): Pioneering Phage Therap

http://beyondspx.com/2024/08/03/armata-pharmaceuticals-inc-armp-pioneering-phage-therapeutics-to-combat-antibiotic-resistance/
MikeTester - August 3, 2024

it's going up today

big time,finally after holding this one since last year,well,sometimes it's tough to wait it out,so glta.
coolfooldumbguy - January 28, 2020

still holding this stock

formerly APHB symbol.
coolfooldumbguy - May 22, 2019
View more Bullboard ››

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral properties in Canada. It ...
View More »